MENU

WDNA WisdomTree BioRevolution Fund (WDNA) Forecast, Technical & Fundamental Analysis

The investment seeks to track the price and yield performance, before fees and expenses, of the WisdomTree BioRevolution Index (“index”)... Show more

Category: #Health
A.I.Advisor
Nov 13, 2026

WisdomTree BioRevolution Fund (WDNA) Forecast: Genetics, Weight-Loss Drugs, and the Biotech Cycle Ahead

Key Takeaways

  • Macro sensitivity: A heavily health-care-weighted portfolio links WDNA's future outlook to interest-rate policy, since long-duration growth and clinical-stage biotech names are especially sensitive to discount-rate shifts.
  • Structural growth drivers: GLP-1 (glucagon-like peptide-1) weight-loss therapies, genomic diagnostics, and cell and gene editing represent multi-year demand themes that could support the underlying index.
  • Portfolio concentration vs. breadth: A modified equal-weight approach tempers single-stock dominance but leaves meaningful small- and mid-cap exposure, amplifying both upside and volatility.
  • Catalyst-rich pipeline: Upcoming clinical-trial readouts, regulatory decisions, and product launches among top holdings are likely to drive performance more than broad market beta.
  • Liquidity considerations: With a modest asset base, the fund's structural risks include potential bid-ask spreads and trading costs that investors should weigh against its thematic exposure.
  • Rebalancing events: The index undergoes a semi-annual rebalancing that can reshuffle single-name weights and alter future portfolio exposure.

Portfolio Exposure and ETF Strategy Overview

The WisdomTree BioRevolution Fund (WDNA) is a passively managed exchange-traded fund that seeks to track the WisdomTree BioRevolution Index, a modified equally weighted benchmark of developed-market companies positioned to be transformed by advancements in genetics and biotechnology. The fund generally uses a representative sampling strategy, investing in a subset of securities whose risk and return characteristics resemble the index as a whole.

The portfolio is dominated by health care, which typically accounts for roughly 88% to 93% of assets, with smaller allocations to basic materials and consumer staples reflecting agricultural, food, and industrial biology themes. Geographic exposure skews heavily toward the United States (roughly 85% or more), with modest exposure to developed Europe and Australia. The fund is classified as non-diversified and carries a net expense ratio of 0.45%.

Among the largest positions are names spanning established pharmaceutical leaders and high-growth biotech. Eli Lilly (LLY) anchors the metabolic-disease franchise, while Twist Bioscience (TWST), Moderna (MRNA), and 10x Genomics (TXG) provide exposure to synthetic biology, messenger RNA (mRNA) therapeutics, and genomics tools. Diagnostic and data names such as Natera (NTRA) and Tempus AI (TEM) represent the growing precision-medicine layer, while Thermo Fisher Scientific (TMO) offers diversified life-science infrastructure. This mix positions the fund across the full biotech value chain, from drug discovery to diagnostics and agricultural inputs.

Major Catalysts Ahead

Several events could materially shape WDNA's trajectory over the coming quarters:

  • Clinical and regulatory milestones: Late-stage trial readouts and FDA (U.S. Food and Drug Administration) decisions, including PDUFA (Prescription Drug User Fee Act) action dates for therapies in oncology and rare disease, can trigger sharp repricing among small- and mid-cap holdings.
  • GLP-1 and obesity pipeline evolution: Developments in oral weight-loss candidates and next-generation metabolic drugs could reinforce the commercial leadership of large holdings while boosting emerging challengers.
  • Genomics and diagnostics adoption: Expansion of liquid-biopsy and whole-genome sequencing platforms could accelerate recurring-revenue growth for diagnostics-focused constituents.
  • Interest-rate trajectory: Federal Reserve policy directly influences the valuation of unprofitable, long-duration biotech equities, making rate expectations a key swing factor.
  • Index rebalancing: Semi-annual reviews may alter weightings and sector tilt, subtly shifting the fund's future risk profile.
  • Fund flows and sentiment: Risk appetite toward thematic health-care ETFs can influence demand, though WDNA's modest AUM (assets under management) suggests flows remain a secondary factor.

Sector, Index, and Macroeconomic Outlook

The macro environment is pivotal for a portfolio so concentrated in innovation-driven health care. Biotechnology valuations are inversely related to long-term interest rates, because much of their value lies in future cash flows; a higher-for-longer rate backdrop tends to compress valuations, while rate cuts historically ease financing conditions for capital-intensive drug developers. Inflation trends also matter indirectly, affecting both borrowing costs and the pricing environment for pharmaceuticals and agricultural products.

On the sector outlook, the long-term case for genomics and precision medicine remains intact, supported by falling sequencing costs, growing adoption of molecular diagnostics, and expanding therapeutic applications. The agricultural biology and food-ingredient sleeve, exposed through names such as Corteva (CTVA) and Darling Ingredients (DAR), ties the fund to global food demand and sustainability themes. Because the underlying index is equally weighted, market trends favoring mega-cap drugmakers over smaller biotech can shift relative performance, underscoring the importance of breadth in the portfolio exposure.

Trend Prediction Engine

Tickeron's Trend Prediction Engine is an AI-powered forecasting tool designed to help traders and investors assess whether an asset such as a stock or ETF may trend bullish, bearish, or sideways over the coming week or month. By analyzing historical price patterns and developing momentum, the tool aims to surface potential breakouts, reversals, or consolidation phases before they fully materialize. Users can explore predictions across a wide range of tradable instruments, review searchable prediction categories with historical context, and set up alert-oriented functionality to stay informed of shifting conditions. For those monitoring evolving themes in biotechnology and genomics, the Trend Prediction Engine can serve as a complementary lens on near-term directional signals alongside fundamental analysis.

Long-Term Outlook and Structural Trends

Over the long term, WDNA's trajectory is tied to durable structural themes rather than short-term market cycles. Advances in gene editing, cell therapy, mRNA platforms, and synthetic biology continue to broaden the addressable market for the underlying companies. Demographic trends, including an aging global population and rising chronic-disease burden, support sustained demand for innovative therapeutics and diagnostics. Meanwhile, the convergence of biology with computing power is fueling the growth of AI-driven drug discovery and genomics-data platforms, potentially lowering development costs and accelerating product pipelines.

These structural tailwinds must be balanced against cyclical realities. Biotechnology is a capital-intensive sector whose funding environment ebbs and flows with interest-rate cycles and venture-capital activity. A prolonged high-rate environment could constrain early-stage innovation, while easing financial conditions could reinvigorate the clinical-stage segment that forms a meaningful share of the fund's mid- and small-cap sleeve. Market structure changes, such as the growth of passive thematic investing and evolving regulatory frameworks for novel therapies, may also shape how capital flows into bio-revolution exposures over time. Investors evaluating this ETF forecast should weigh both the long-run innovation opportunity and the inherent volatility of a non-diversified, health-care-centric portfolio.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Interact to see
Advertisement
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
MCOW21.49N/A
N/A
Pacer S&P MidCap 400 Quality FCF Aristocrats ETF (MCOW)
HDG51.83-0.68
-1.29%
ProShares Hedge Replication ETF (HDG)
KJAN43.48-0.79
-1.79%
Innovator U.S. Small Cap Power Buffer ETF - January (KJAN)
EXUS24.00-0.64
-2.58%
Nomura ETF Trust Nomura Focused International Core ETF (EXUS)
FSEP53.42-1.46
-2.67%
FT Vest U.S. Equity Buffer ETF - September (FSEP)
WDNA Holdings
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FSEP53.42-1.46
-2.67%
FT Vest U.S. Equity Buffer ETF - September (FSEP)
EXUS24.00-0.64
-2.58%
Nomura ETF Trust Nomura Focused International Core ETF (EXUS)
KJAN43.48-0.79
-1.79%
Innovator U.S. Small Cap Power Buffer ETF - January (KJAN)
HDG51.83-0.68
-1.29%
ProShares Hedge Replication ETF (HDG)
MCOW21.49N/A
N/A
Pacer S&P MidCap 400 Quality FCF Aristocrats ETF (MCOW)

WDNA and ETFs

Correlation & Price change

A.I.dvisor tells us that WDNA and XBI have been poorly correlated (+-1% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that WDNA and XBI's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To WDNA
1D Price
Change %
WDNA100%
-3.12%
XBI - WDNA
-1%
Poorly correlated
-2.73%
IBB - WDNA
-3%
Poorly correlated
-2.05%
XLV - WDNA
-5%
Poorly correlated
-0.12%
IYH - WDNA
-5%
Poorly correlated
-0.32%
VHT - WDNA
-5%
Poorly correlated
-0.40%
More
WisdomTree BioRevolution Fund (WDNA) Forecast: Genetics, Weight-Loss Drugs, and the Biotech Cycle Ahead